PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 74238

Title: Advances in Postoperative Adjuvant Therapy for Primary Liver Cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03552327

Position: Peer Reviewer

Academic degree: BSc, DPhil

Professional title: Associate Professor

Reviewer’s Country/Territory: Malaysia

Author’s Country/Territory: China

Manuscript submission date: 2021-12-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-06 21:25

Reviewer performed review: 2022-01-10 09:39

Review time: 3 Days and 12 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[Y] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[Y] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Reviewer: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The authors have comprehensively reviewed the literature on the advances in postoperative adjuvant therapy for hepatocellular carcinoma (HCC). In general, the manuscript was well written and well organised. This review provides a timely update on the recent advances in the treatment of postoperative metastasis and recurrence of HCC. However, I would like to highlight a few points to add on, as below:
1. GLOBOCAN data should be updated to reveal the most recent statistics in 2021. 2. Nearly 25% of all HCCs harbour mutations including TERT, TP53 and CTNNB1, with the translational potential for clinical impact. Although they have remained undruggable for a long time, I believe these should be discussed, if not mentioned in the review. 3. RCTs and meta-analyses based on RCTs exploring the efficacy of adjuvant interferon therapy for HCC should also be included. 4. Include studies (updates) on Vitamin K2 analog and retinoids, as well as heparanase inhibitor PI-88 in postoperative HCC.
Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 74238

Title: Advances in Postoperative Adjuvant Therapy for Primary Liver Cancer

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03538158

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: China

Manuscript submission date: 2021-12-29

Reviewer chosen by: Qi-Gu Yao

Reviewer accepted review: 2022-02-24 16:07

Reviewer performed review: 2022-03-06 04:10

Review time: 9 Days and 12 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

Zeng et al. reviewed “Advances in postoperative adjuvant therapy for primary liver cancer”. 1. In abstract section, How was immune checkpoint inhibitors (ICI)? 2. In Introduction section, “HCC often occurs in the setting of chronic liver disease with or without cirrhosis, and the most common etiologies are chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, alcohol intake, and aflatoxin exposure.” How was NASH?